RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $50 price target.
February 07, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $50 price target on Arrowhead Pharma.
The reiteration of an Outperform rating and maintenance of a $50 price target by a reputable analyst like Luca Issi from RBC Capital could positively influence investor sentiment towards ARWR, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100